Oxford's OMass Therapeutics Draws $310M to Test Two Experimental Medicines in Patients
Bain Capital Life Sciences, Forbion and Novo Holdings co-led the oversubscribed Series C, which will carry the adrenal-disease candidate OMS1620 through Phase 2 development.
OMass Therapeutics, an Oxford-based biotechnology company, has raised $310 million (£230 million) in an oversubscribed Series C financing, the company announced on October 15, 2026. The round was co-led by Bain Capital Life Sciences, Forbion and Novo Holdings.
OMass develops small-molecule medicines aimed at diseases involving difficult biological targets. The company originated from research conducted in Professor Dame Carol Robinson's laboratory at the University of Oxford. Its drug-discovery platform combines native mass spectrometry, specialized biochemistry and chemistry techniques to study proteins and their interactions in biologically relevant environments — an approach intended to identify medicines that can act on targets that have historically been hard to address.
Additional investors in the round include Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences. Existing shareholders Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and the University of Oxford also participated. OMass did not disclose a valuation.
The largest portion of the new financing will support development of OMS1620, an experimental medicine targeting the melanocortin-2 receptor. OMass is developing the drug for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, conditions that involve abnormal hormone regulation, and plans to advance it through Phase 2 clinical development.
The company will also use the proceeds to support an experimental SLC15A4 inhibitor intended for lupus and other diseases associated with abnormal immune signaling.
The raise places OMass among the larger biotech financings in a day that saw more than $1.51 billion flow into ten startups, a total dominated by AI infrastructure deals such as Modal's $750 million Series D. Where those rounds fund computing capacity and networking, OMass is financing clinical development, where the outcome depends on generating convincing evidence that experimental medicines work safely in patients.
That distinction shapes the risk profile. A discovery platform can identify potential medicines, but clinical trials must establish safety and efficacy in patients, and even substantial financing cannot eliminate that uncertainty. The next material valuation events for OMass will likely depend on clinical data rather than the funding announcement itself.
The participation of Bain Capital Life Sciences, Forbion, Novo Holdings and a roster of established biotechnology investors indicates confidence in the company's pipeline and research approach. The round also reflects a broader willingness among investors to fund businesses whose capabilities require years of research, specialized facilities, regulatory expertise and operating experience — a different bet from the software economics that dominated the rest of the day's activity.